Lead item – a direct competitor exiting the space
Certara announced April 22, 2026 (closed May 8, 2026) the sale of its entire Regulatory and Medical Writing business to
Veristat, for up to $135M ($85M cash + $15M escrow + up to $35M earn-out) — a ~220-employee, $50M-revenue unit. Certara's stated rationale: refocus on MIDD/Clinical Intelligence and AI-integrated modeling and simulation, explicitly exiting medical-writing services. Every Certara medical-writing client is mid-forced-transition to a new vendor, new platform, and new validation burden right now.
Ask: "Certara just exited medical-writing services entirely to refocus on modeling and simulation, and their clients are mid-transition to Veristat right now — is Indegene seeing any of that displaced demand, and how does a strategist in this seat position for a client coming off a forced platform switch?"
Supporting context
| Veeva / IQVIA | Eight-year legal dispute resolved August 2025, opening a five-year migration window (through September 2030) for Veeva's Salesforce-dependent CRM customers — a large, still-active multi-year switching event running concurrently with the Certara divestiture, same general pattern of forced vendor transition in life sciences tech. |
| Switching cost scale | Industry estimate: AI vendor lock-in costs run 19-34% of contract value in switching expenses (data migration, revalidation, regulator notification) across the 150+-vendor pharma AI landscape — framing language for why a forced transition like Certara's clients are facing is expensive and slow, not a quick vendor swap. |
Searched and came up thin – said plainly, not stretched
- Cost/ROI setbacks: no named pharma company found that paused or cancelled a GenAI medical-writing initiative after disappointing ROI. Only generic "pilots fail" industry commentary exists, naming zero specific companies with a documented reversal.
- Workforce/labor friction: no union activity, strike, or named-company layoff tied specifically to AI-generated medical-writing content. AMWA has run member surveys and webinars on the topic but no formal position statement or job action in 2026.
- Data privacy/security incidents: no incident found of a GenAI medical-writing or regulatory-content tool itself exposing data. Real 2026 breaches exist (Amgen, disclosed Aug 1; Novo Nordisk, disclosed June 11, ~700K files including clinical trial data) but both trace to credential/cloud-access compromise, not a content-generation tool failure — don't conflate the two in the room.